News from bioinvent A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 23, 2020, 05:03 ET BioInvent Enrolls First Patient in Phase I/IIa Trial of BI-1206 in Combination With KEYTRUDA® for the Treatment of Patients With Solid Tumors

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Jun 22, 2020, 09:48 ET BioInvent Presents Proof-of-concept Data for two TNFR2-targeting Antibodies

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Jun 22, 2020, 09:33 ET BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Jun 18, 2020, 09:18 ET Proposal for a New Board Member to be Elected at the Extraordinary General Meeting on July 3, 2020

BioInvent International AB ("BioInvent") (OMXS: BINV) today announces, on behalf of the nomination committee and major shareholders, the proposal to...


May 15, 2020, 02:47 ET BioInvent and Transgene Present Preclinical Data Demonstrating BT-001's Powerful Activity Against Solid Tumors

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


May 15, 2020, 02:38 ET BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development

BioInvent International AB ("BioInvent") (OMXS: BINV) today announces the presentation of promising new data on its anti-tumor necrosis factor...


Apr 30, 2020, 02:20 ET BioInvent Signs New Manufacturing Agreement With U.S. Cell Therapy Company

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Apr 28, 2020, 02:15 ET BioInvent Interim Report January 1 - March 31, 2020

Promising progress reported for BI-1206 in combination with rituximab "We have made a strong start to 2020 and remain on track to deliver on our...


Apr 14, 2020, 02:24 ET BioInvent Reports Promising Progress in Phase I/lla Trial of Lead Program BI-1206 in Combination with Rituximab

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today provides a preliminary insight into progress of its Phase I/IIa trial of ...


Apr 08, 2020, 06:37 ET BioInvent: Annual Report 2019

BioInvent International AB (publ) (BINV) today announced that the Annual Report for 2019 is available at the company's website, www.bioinvent.com...


Mar 26, 2020, 09:59 ET BioInvent Postpones the Annual General Meeting and Provides an Update on the Current Situation in Respect of COVID-19

BioInvent International AB ("BioInvent") (OMXS: BINV) today announces that the Board of Directors has resolved to postpone the annual general meeting ...


Mar 24, 2020, 09:22 ET BioInvent and SkylineDx to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206

BioInvent International AB ("BioInvent") (OMXS: BINV) today announces an agreement with SkylineDx to characterize the gene expression and...


Mar 03, 2020, 03:02 ET BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Feb 27, 2020, 01:52 ET BioInvent Financial Statement January 1 - December 31, 2019

"We are proud that we have delivered on our goals for the year and feel confident that we will continue to do so in 2020, with a number of important...


Feb 24, 2020, 09:12 ET Invitation to Presentation of BioInvent's Fourth Quarter Report 2019 on February 27, 2020

BioInvent International AB (OMXS: BINV) will issue its interim report for the fourth quarter 2019 on Thursday February 27 at 7.30 a.m. CET, followed...


Dec 23, 2019, 04:23 ET BioInvent Announces Selection of Second Target and Extension of the Research Collaboration and License Agreement With Pfizer Inc.

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that Pfizer Inc. ("Pfizer") (NYSE: PFE) has selected the...


Dec 18, 2019, 02:14 ET BioInvent Has Entered Into a Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1206 in Combination With KEYTRUDA® in Advanced Solid Tumors

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it has entered into a clinical trial collaboration and...


Dec 11, 2019, 02:57 ET BioInvent and Transgene Announce Compelling Preclinical Data for BT-001 in Solid Tumors

BioInvent International AB (publ) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Nov 08, 2019, 02:32 ET BioInvent to Present BI-1206 Preclinical Data in Mantle Cell lymphoma at ASH 2019

BioInvent International AB (publ) (OMXS: BINV) today announces it will make a poster presentation with preclinical data on BI-1206 at the annual...


Oct 23, 2019, 07:45 ET BioInvent Signs Manufacturing Agreement With Cancer Research UK Expected to Generate Approximately SEK 30 Million (~$3 Million)

BioInvent International AB (publ) (OMXS: BINV) today announces it has concluded a production agreement with Cancer Research UK, the world's largest...


Aug 22, 2019, 02:44 ET BioInvent: Interim Report January 1 - June 30, 2019

"We are executing according to plan. Our lead candidate BI-1206 has shown encouraging initial data in hematological cancers, and has now also entered ...


Aug 21, 2019, 03:17 ET BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors

BioInvent International AB (publ) (OMXS: BINV), a company focused on the discovery and development of novel and first-in-class immuno-modulatory...


Aug 20, 2019, 04:52 ET BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Combination With Ranibizumab, for DME

BioInvent International AB's (publ) (OMXS: BINV) partner Oxurion NV has today reported topline data from a Phase lla study evaluating THR-317, a...


Aug 15, 2019, 06:33 ET USPTO Intends to Grant BioInvent Patent Relating to BI-1206

BioInvent International AB (OMXS: BINV) today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance...


Aug 14, 2019, 06:42 ET Invitation to Presentation of BioInvent's Interim Report Q2-2019 on August 22, 2019

BioInvent International AB (OMXS: BINV) will issue its interim report for the second quarter 2019 on Thursday August 22 at 8.30 a.m. CEST, followed...